Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

71.04 -2.52 (-3.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 814,533
Open 73.56
Bid (Size) 70.11 (5)
Ask (Size) 72.65 (1)
Prev. Close 73.56
Today's Range 70.22 - 74.17
52wk Range 56.05 - 120.03
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 No-Brainer Stocks to Buy for Under $100 Right Now
These stocks might not remain under $100 for too much longer. 
Via The Motley Fool
NovoCure's Return On Capital Employed Overview
 
Via Benzinga

Performance

YTD
+4.56%
+4.56%
1 Month
+6.16%
+6.16%
3 Month
-8.10%
-8.10%
6 Month
+1.40%
+1.40%
1 Year
-11.62%
-11.62%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
4 Analysts Have This to Say About NovoCure
Via Benzinga
Should You Buy Novocure Stock Right Now?
Via The Motley Fool
NovoCure (NVCR) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Novocure Stock Dips As Q1 Earnings Miss Estimates, Higher Costs Hurt Bottom Line
Via Benzinga
NovoCure: Q1 Earnings Insights
Via Benzinga
What 4 Analyst Ratings Have To Say About NovoCure
Via Benzinga
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
The 3 Most Promising Healthcare Tech Stocks for April 2023
Via InvestorPlace
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
2 Best Defensive Stocks to Buy in March
Via The Motley Fool
NovoCure Earnings Perspective: Return On Capital Employed
Via Benzinga
Novocure to Report First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Kristin Stafford Joins Novocure Board of Directors
From Novocure
Via Business Wire
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Why NovoCure Stock Is Falling Today
Via The Motley Fool
NovoCure (NVCR) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
2 Stocks That Could Rebound and Rise 30% or More in 2023
Via The Motley Fool
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.